JFG
TVTX icon

Jefferies Financial Group’s Travere Therapeutics TVTX Stock Holding History

Jefferies Financial Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,000
Closed -$1.49M – 2053
2026
Q1 		$1.49M Buy
50,000
+31,000
+163% +$927K 0.01% 761
2025
Q4 		$726K Buy
19,000
+5,000
+36% +$163K ﹤0.01% 1220
2025
Q3 		$335K Buy
+14,000
New +$263K ﹤0.01% 1180

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jefferies Financial Group's TVTX Position: Q2 2026 in Review

Jefferies Financial Group increased its Travere Therapeutics (TVTX) stake by 500% in Q2 2026, buying an estimated $1.07M and bringing the position to 29,037 shares worth $1.65M. The position accounts for 0.01% of the portfolio, ranked #758.

Jefferies Financial Group first reported a position in TVTX in Q1 2023 and has held it in 7 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Jefferies Financial Group held 29,037 shares of Travere Therapeutics worth $1.65M as of Q2 2026.
  • Jefferies Financial Group bought 24,200 Travere Therapeutics shares in Q2 2026, an estimated $1.07M.
  • Travere Therapeutics made up 0.01% of Jefferies Financial Group's portfolio in Q2 2026, its #758 holding.
  • Jefferies Financial Group first reported a position in Travere Therapeutics in Q1 2023 and has held it in 7 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.